The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.
作者： Marco Barbieri , John B Wong , Michael Drummond
DOI: 10.2165/00019053-200523060-00007
关键词:
摘要: Objective: To estimate the cost effectiveness (from UK NHS and personal social service perspectives) of infliximab plus methotrexate (MTX) compared with MTX alone, in treatment patients severe rheumatoid arthritis (RA) who were not adequately controlled on disease-modifying antirheumatic drugs resistant to MTX.
springer.com
sci-hub.se 参考文章(28)
W M O'Fallon, S E Gabriel, C S Crowson, M E Campion, Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. The Journal of Rheumatology. ,vol. 24, pp. 43- 48 ,(1997)
M A Cathey, D J Hawley, J F Fries, P W Spitz, S M Kleinheksel, F Wolfe, The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis. The Journal of Rheumatology. ,vol. 15, pp. 1480- 1488 ,(1988)
Weinblatt Me, Methotrexate in rheumatoid arthritis. Bulletin on The Rheumatic Diseases. ,vol. 42, pp. 4- 7 ,(1993)
Deborah P. Lubeck, Patricia W. Spitz, James F. Fries, Frederick Wolfe, Donald M. Mitchell, Sanford H. Roth, A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis & Rheumatism. ,vol. 29, pp. 488- 493 ,(1986) , 10.1002/ART.1780290405
M. J. H. WIJNANDS, M. A. VAN'T HOF, M. A. VAN LEEUWEN, M. H. VAN RIJSWIJK, L. B. A. VAN DE PUTTE, P. L. C. M. VAN RIEL, LONG-TERM SECOND-LINE TREATMENT: A PROSPECTIVE DRUG SURVIVAL STUDY Rheumatology. ,vol. 31, pp. 253- 258 ,(1992) , 10.1093/RHEUMATOLOGY/31.4.253
Ravinder Maini, E William St Clair, Ferdinand Breedveld, Daniel Furst, Joachim Kalden, Michael Weisman, Josef Smolen, Paul Emery, Gregory Harriman, Marc Feldmann, Peter Lipsky, Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial The Lancet. ,vol. 354, pp. 1932- 1939 ,(1999) , 10.1016/S0140-6736(99)05246-0
C. H. van Jaarsveld, J. W. Jacobs, A. J. Schrijvers, A. H. Heurkens, H. C. Haanen, J. W. Bijlsma, Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study. Rheumatology. ,vol. 37, pp. 837- 847 ,(1998) , 10.1093/RHEUMATOLOGY/37.8.837
Gisela Kobelt, Kerstin Eberhardt, Linus J�nsson, Bengt J�nsson, Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis & Rheumatism. ,vol. 42, pp. 347- 356 ,(1999) , 10.1002/1529-0131(199902)42:2<347::AID-ANR18>3.0.CO;2-P
J. Raftery, NICE: faster access to modern treatments? Analysis of guidance on health technologies BMJ. ,vol. 323, pp. 1300- 1303 ,(2001) , 10.1136/BMJ.323.7324.1300
Jake Jacobs, Judith A. Keyserling, Melvin Britton, G.J. Morgan, Jack Wilkenfeld, H. Christina Hutchings, The total cost of care and the use of pharmaceuticals in the management of rheumatoid arthritis: the Medi-Cal program. Journal of Clinical Epidemiology. ,vol. 41, pp. 215- 223 ,(1988) , 10.1016/0895-4356(88)90124-2